About 23 results found for searched term "MP-A08" (0.123 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M13355 | MP-A08 | SPHK |
| Mp-a08 is a highly selective inhibitor of ATP-competitive sphingine kinase (SPHK1) with Ki value of 6.9 μM. | ||
| M1984 | PF-04691502 | PI3K |
| PF-04691502 is a potent and selective, ATP-competitive PI3K/mTOR inhibitor with IC50 of 7.5 nM and 3.8 nM of AKT T308 and AKT S473, respectively. | ||
| M4755 | Apioside | NO Synthase |
| Apiin is one of the main components of Apium graveolens leaves and has anti-inflammatory properties. Apiin could inhibit nitrite (NO) production in vitro (IC50 = 0.08 mg/mL) and iNOS expression in LPS-activated J774.A1 cells (IC50 = 0.049 mg/mL). | ||
| M6158 | ARQ-087 | FGFR |
| Derazantinib | ||
| ARQ 087 is a novel, ATP competitive, small molecule, multi-kinase inhibitor with potent in vitro and in vivo activity against FGFR addicted cell lines and tumors. ARQ 087 exhibited IC50 values of 1.8 nM for FGFR2, and 4.5 nM for FGFR1 and 3. | ||
| M9222 | LY3200882 | TGF-β Receptor |
| LY3200882 is a potent, highly selective, ATP-competitive and orally active TGF-β receptor type 1 (ALK5) inhibitor with an IC50 of 38.2 nM. LY3200882 is also used as an immune modulatory agent. | ||
| M10561 | IMP-1088 | DNA/RNA Synthesis |
| IMP1088 | ||
| IMP-1088 is a novel potent and selective blocker of N-myristoylation in cells. IMP-1088 is also a potent human N-myristoyltransferases NMT1 and NMT2 dual inhibitor with IC50s of <1 nM for HsNMT1 and HsNMT2. | ||
| M10831 | HPK1-IN-3 | MAPKAPK2/MAP3K/MAP4K |
| HPK1-IN-3 is a potent selective ATP competitive hematopoietic progenitor kinase 1 (HPK1; MAP4K1) inhibitor,IC50 0.25 nM. HPK1-IN-3 has IL-2 cell potency, EC in human peripheral blood mononuclear cells (PBMCs).50 108 nM. | ||
| M11247 | CAN508 | CDK |
| CAN508 was an effective AND ATP-competitive inhibitor of CDK9/cyclin T1 with IC50 of 0.35 μM. CAN508 is 38 times more selective for CDK9/cyclin T1 than other CDK/cyclin. CAN508 has antitumor activity. | ||
| M14227 | LY450108 | GluR |
| LY450108 is a potent AMPA receptor potentiator. LY450108 has the potential for depression and Parkinson's disease research. | ||
| M27717 | SB 242084 dihydrochloride | 5-HT Receptor |
| SB 242084 dihydrochloride is a selective, competitive and high-affinity (pKi=9.0) 5-HT2C receptor antagonist (crosses the blood-brain barrier). SB 242084 dihydrochloride increases basal activity of dopaminergic neurons in the ventral tegmental area (VTA) of the midbrain and dopamine release in the vomeronasal nucleus. SB 242084 dihydrochloride also increases mitochondrial gene expression and oxidative metabolism via 5-HT2A receptor. SB 242084 dihydrochloride has good research potential in the negative symptoms of anxiety, depression and schizophrenia, as well as in acute organ damage. | ||
| M28007 | PF-05198007 | Sodium Channel |
| PF-05198007 is a potent, orally active and selective arylsulfonamide Nav1.7 inhibitor. PF-05198007 is a compound with a similar pharmacodynamic profile to PF-05089771. | ||
| M28062 | PF-4950834 | ROCK |
| PF-4950834 is a potent, selective, orally bioavailable, ATP-competitive rho kinase inhibitor with IC50 values of 8.35 nM and 33.12 nM against ROCK2 and ROCK1, respectively. PF-4950834 inhibits neutrophil migration. | ||
| M28259 | (Rac)-CCT 250863 | Apoptosis |
| (Rac)-CCT 250863 (compound rac-21) is a selective and reversible NEK 2 inhibitor with an IC50 of 0.073 µM. (Rac)-CCT 250863 shows good effects of inducing cell cycle arrest and also can antiproliferative in cells (Pomalidomide sensitive/resistant). (Rac)-CCT 250863 induces apoptosis when combines with Pomalidomide. | ||
| M28307 | PRE-084 | Sigma Receptor |
| PRE-084 is a highly selective σ1 receptor (S1R) agonist, with an IC50 of 44 nM. PRE-084 exhibits good neuroprotective effects, can improve motor function and motor neuron survival in mice. PRE-084 also can ameliorate myocardial ischemia-reperfusion injury in rats by activating the Akt-eNOS pathway. | ||
| M28860 | EGFR/ErbB-2/ErbB-4 inhibitor-2 | EGFR/HER2 |
| EGFR/ErbB-2/ErbB-4 inhibitor-2 (Compound 5) is a EGFR and ErbB inhibitor with IC50s of 0.017 μM, 0.08 μM, 1.91 μM. | ||
| M28863 | PD-089828 | FGFR |
| PD-089828 is an ATP competitive inhibitor of FGFR-1, PDGFR-β and EGFR (IC50s=0.15, 1.76, and 5.47 µM, respectively) and a noncompetitive inhibitor of c-Src tyrosine kinase (IC50=0.18 µM). PD-089828 also inhibits MAPK with an IC50 of 7.1 µM. PD-089828 inhibits PDGF-, EGF- and bFGF-mediated tyrosine kinase receptor autophosphorylation in vitro. PD-089828 has a long-lasting cellular activity. | ||
| M29260 | Indolmycin | Antibiotic |
| TAK-083; PA-155A | ||
| Indolmycin (TAK-083), an antibiotic, is a competitive inhibitor of prokaryotic tryptophanyl-tRNA synthetase (TrpS). Indolmycin (TAK-083) possesses both anti-viral and anti-bacterial activity. | ||
| M29340 | SPC 839 | NF-κB |
| SPC 839 (compound 10) is an orally active inhibitor of AP-1 and NF-kB mediated transcriptional activation with IC50 of 0.008 μM. | ||
| M29697 | MRE3008F20 | Adenosine Receptor |
| MRE3008F20 is a highly efficient, highly selective and radioactive adenosine A3 receptor (AA3R) antagonist (Ki=1.8 nM). MRE3008F20 effectively antagonises Cl-IB-MECA-induced cAMP production in resting lymphocytes with an IC50 value of 5 nM. MRE3008F20 can be used in the study of AA3R. | ||
| M29863 | ESI-08 | Ras |
| ESI-08 is a potent and selective EPAC antagonist, which can completely inhibit both EPAC1 and EPAC2 (IC50 of 8.4 μM) activity. ESI-08 selectively blocks cAMP-induced EPAC activation, but does not inhibit cAMP-mediated PKA activation. | ||
| M30916 | HS56 | Pim |
| HS56 is an ATP-competitive dual Pim/DAPK3 inhibitor with Ki values of 0.26, 0.208, 2.94, and ＞100 μM for DAPK3, Pim-3, Pim-1, and Pim-2, respectively. HS56 inhibits LC20 phosphorylation and smooth muscle contraction. HS56 decreases blood pressure in spontaneously hypertensive mice. HS56 can be used in research of hypertension. | ||
| M55656 | CW 008 | PKA |
| CW008; CW-008 | ||
| CW 008 is a CREB or PKA pathway agonist. CW 008 also is a stem cell differentiating agent. CW008 promotes osteogenesis by activating cAMP/PKA/CREB signaling pathway and inhibiting leptin secretion. CW 008 stimulates osteoblast differentiation of human MSCs and increases bone formation in ovariectomized mice. | ||
| M57222 | (Z)-Orantinib | VEGFR/PDGFR |
| (Z)-Orantinib ((Z)-SU6668) is a potent, selective, orally active and ATP competitive inhibitor of Flk‐1/KDR, PDGFRβ, and FGFR1, with IC50s of 2.1, 0.008, and 1.2 µM, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
